ArticleGene therapy2000
Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo.
Article in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 50 citations in OpenAlex.
- Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Histone deacetylase inhibition enhances adenoviral vector transduction in inner ear tissue.Neuroscience · 2010Article
- In Vivo Cellular Imaging for Translational Medical Research.Current medical imaging reviews · 2009Article
- Article
- HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.Genetic vaccines and therapy · 2007Article
- Quantitative and mechanism-based investigation of post-nuclear delivery events between adenovirus and lipoplex.Nucleic acids research · 2007Article
- Sustained expression after nonviral ocular gene transfer using mammalian promoters.Gene therapy · 2006Article
- Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2006Article
- Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle.Gene therapy · 2005Article
- Promyelocytic leukemia protein-induced growth suppression and cell death in liver cancer cells.Cancer gene therapy · 2005Article
- Recombinant adeno-associated virus type 2-mediated gene delivery into theGenetic vaccines and therapy · 2004Article
- Article
- Non-viral gene delivery in skeletal muscle: a protein factory.Gene therapy · 2003Review
- Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1.The Journal of clinical investigation · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) promoter is often present in recombinant adenovirus vectors (AdVs) suitable for gene therapy, ensuring high levels of transgene production in a wide range of hosts. Despite this characteristic, the presence of the AdV genome in target cells and tissues typically lasts longer than transgene production that may be rapidly extincted by ill-defined silencing mechanisms. In the present article, it is reported that transcriptionally active drugs, retinoic acid (RA) and histone deacetylase inhibitor trichostatin A (TSA), enhance AdV transgene expression in infected cells and tissues. The association of RA and TSA increased more than seven-fold above control the activity of AdVs encoding for LacZ or VEGF165. This effect was, at least in part, mediated by the direct activation of retinoic acid receptors. Finally, administration of RA and TSA alone at days 0 and 5 after infection prolonged transgene production up to 21 days after infection versus 6-8 days in untreated controls. These results indicate that transcriptionally active drugs improve AdV function and may represent a novel strategy to more efficiently design AdVs for gene therapy interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.